EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Detection of oxaliplatin- and cisplatin-DNA lesions requires different global genome repair mechanisms that affect their clinical efficacy

Jana Slyskova iD, Alba Muniesa-Vargas, Israel Tojal da Silva iD, Rodrigo Drummond, Jiyeong Park, David Häckes, Isabella Poetsch, Cristina Ribeiro-Silva, Amandine Moretton iD, Petra Heffeter, Orlando D Schärer, Wim Vermeulen iD und 2 weitere

NAR Cancer · 11.10.2023 · 5 (4)

DOI: 10.1093/narcan/zcad057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, online erschienen am 05.12.2023. Verfasst von Jana Slyskova und 13 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer Research, Medical University of Vienna, A-1090 Vienna, Austria. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EMBO, European Commission, Austrian Science Fund.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic efficacy of cisplatin and oxaliplatin depends on the balance between the DNA damage induction and the DNA damage response of tumor cells. Based on clinical evidence, oxaliplatin is administered to cisplatin-unresponsive cancers, but the underlying molecular causes for this tumor specificity are not clear. Hence, stratification of patients based on DNA repair profiling is not sufficiently utilized for treatment selection. Using a combination of genetic, transcriptomics and imaging approaches, we identified factors that promote global genome nucleotide excision repair (GG-NER) of DNA-platinum adducts induced by oxaliplatin, but not by cisplatin. We show that oxaliplatin-DNA lesions are a poor substrate for GG-NER initiating factor XPC and that DDB2 and HMGA2 are required for efficient binding of XPC to oxaliplatin lesions and subsequent GG-NER initiation. Loss of DDB2 and HMGA2 therefore leads to hypersensitivity to oxaliplatin but not to cisplatin. As a result, low DDB2 levels in different colon cancer cells are associated with GG-NER deficiency and oxaliplatin hypersensitivity. Finally, we show that colon cancer patients with low DDB2 levels have a better prognosis after oxaliplatin treatment than patients with high DDB2 expression. We therefore propose that DDB2 is a promising predictive marker of oxaliplatin treatment efficiency in colon cancer.

Autor:innen und Institutionen

  • Center for Cancer Research, Medical University of Vienna, A-1090 Vienna, Austria.
  • CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, A-1090 Vienna, Austria.
  • Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
  • Laboratory of Bioinformatics and Computational Biology, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil.
  • Center for Genomic Integrity, Institute for Basic Science, Ulsan 44919, Republic of Korea.
  • Research Cluster "Translational Cancer Therapy Research", A-1090 Vienna, Austria.

ORCID-Profile: Jana Slyskova, Israel Tojal da Silva, Amandine Moretton, Wim Vermeulen, Hannes Lans

Förderung

  • EMBO
  • European Commission
  • Austrian Science Fund
  • Dutch Cancer Society
  • Netherlands Organization for Scientific Research
  • Oncode Institute
  • European Research Council
  • Korean Institute for Basic Science

Zitieren

APA

Slyskova, J., Muniesa-Vargas, A., da Silva, I. T., Drummond, R., Park, J., Häckes, D., Poetsch, I., Ribeiro-Silva, C., Moretton, A., Heffeter, P., Schärer, O. D., Vermeulen, W., Lans, H., & Loizou, J. I. (2023). Detection of oxaliplatin- and cisplatin-DNA lesions requires different global genome repair mechanisms that affect their clinical efficacy. NAR Cancer, 5(4). https://doi.org/10.1093/narcan/zcad057

Vancouver

Slyskova J, Muniesa-Vargas A, da Silva IT, Drummond R, Park J, Häckes D, et al. Detection of oxaliplatin- and cisplatin-DNA lesions requires different global genome repair mechanisms that affect their clinical efficacy. NAR Cancer. 2023;5(4). doi:10.1093/narcan/zcad057

BibTeX
@article{Slyskova2023,
  author = {Slyskova, Jana and Muniesa-Vargas, Alba and da Silva, Israel Tojal and Drummond, Rodrigo and Park, Jiyeong and Häckes, David and Poetsch, Isabella and Ribeiro-Silva, Cristina and Moretton, Amandine and Heffeter, Petra and Schärer, Orlando D and Vermeulen, Wim and Lans, Hannes and Loizou, Joanna I},
  title = {Detection of oxaliplatin- and cisplatin-DNA lesions requires different global genome repair mechanisms that affect their clinical efficacy},
  journal = {NAR Cancer},
  year = {2023},
  volume = {5},
  number = {4},
  doi = {10.1093/narcan/zcad057}
}
Kostenlos starten →